Avonex Sales Data
| Rank 48 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Avonex U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 48 ( 3) |
$281,554 | -1.43% | 70 | -6.67% |
| Q3 2013 | 45 (4) |
$285,629 | -6.68% | 75 | -14.77% |
| Q2 2013 | 41 (2) |
$306,073 | -9.51% | 88 | -9.28% |
| Q1 2013 | 39 (6) |
$338,236 | -9.05% | 97 | -13.39% |
| Q4 2012 | 33 (4) |
$371,884 | -5.17% | 112 | -8.94% |
| Q3 2012 | 29 ( 4) |
$392,159 | -5.34% | 123 | -6.82% |
| Q2 2012 | 33 (6) |
$414,293 | 6.61% | 132 | 1.54% |
| Q1 2012 | 39 (1) |
$388,623 | 2.22% | 130 | -3.70% |
| Q4 2011 | 38 (5) |
$380,189 | 0.19% | 135 | -2.17% |
| Q3 2011 | 33 | $379,457 | -0.05% | 138 | -1.43% |
| Q2 2011 | 33 (4) |
$379,639 | 2.45% | 140 | -1.41% |
| Q1 2011 | 37 | $370,570 | n/a | 142 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
